News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma.


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35056

Posted on: 10/04/2008

Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma.

Sub-category:

Central Nervous System Tumors

Category:

Central Nervous System Tumors

Meeting:

2008 ASCO Annual Meeting

 Printer Friendly

 E-Mail Article

Abstract No:

2022

Citation:

J Clin Oncol 26: 2008 (May 20 suppl; abstr 2022)

Author(s):

J. N. Rich, A. Desjardins, S. Sathornsumetee, J. J. Vredenburgh, J. A. Quinn, S. Gururangan, A. H. Friedman, H. S. Friedman, D. A. Reardon

Abstract:

Background: Bevacizumab (BV), a neutralizing monoclonal antibody to vascular endothelial growth factor (VEGF), has demonstrated remarkable radiographic response and promising survival benefit in combination with irinotecan in patients with recurrent glioblastoma multiforme (GBM). In this study, we evaluate the efficacy of bevacizumab when combined with etoposide, a topoisomerase inhibitor, in patients with recurrent malignant glioma (MG). Methods: Recurrent patients with no more than three prior episodes of recurrence are eligible, while those with prior BV treatment or prior intracranial hemorrhage are excluded. The primary outcome measure is 6 month progression-free survival. BV is dosed at 10 mg/kg intravenously every other week. Etoposide is orally administered daily (50 mg/m2) for days 1-21 of each 28-day cycle. Results: Fifty-three patients have enrolled including 27 with GBM, 16 with anaplastic astrocytoma, 8 with anaplastic oligodendroglioma and 2 with malignant pleomorphic xanthoastrocytoma. The median age is 48.7 years (range, 25.2-71.2), and patients have had a median of 2 prior progressions (range, 1-3) and 2 prior therapeutic agents (range, 1-7). The most common significant toxicities include neutropenia (grade 3, n=8; grade 4, n=1), thrombosis (grade 3, n=2, grade 4, n=2; grade 5, n=1), hyponatremia (grade 3, n=3) and infection (grade 3, n=2). Two patients developed grade 1 intracranial hemorrhage. Best responses to date include complete response (n=1; 2%); partial response (n=9; 17%), stable disease (n=34; 60%); progressive disease (n=3; 6%). Six patients are too early to assess.Conclusions: Combination of bevacizumab and etoposide is well tolerated in recurrent MG patients and is associated with encouraging radiographic response. Further accrual, treatment and follow-up are ongoing.

Abstract Disclosures

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740